BriaCell Therapeutics (BCTX) Prices Public Offering at $30M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: seekingalpha
- Capital Raise: BriaCell Therapeutics has priced a public offering of 5.37 million units, each consisting of one common share and one warrant, at $5.59 per unit, aiming for gross proceeds of approximately $30 million to fund working capital and advance business objectives.
- Offering Timeline: The public offering is expected to close on January 15, 2026, marking a significant step for the company in the capital markets, despite facing challenges from market volatility.
- Stock Price Reaction: Following the public offering announcement, BriaCell's stock dropped 9.7% during after-market trading on Tuesday, indicating a negative market reaction that could impact investor confidence.
- Use of Proceeds: The company intends to utilize the net proceeds for working capital needs and general corporate purposes, a strategy that aims to support its long-term growth objectives and business expansion.
Analyst Views on BCTX
Wall Street analysts forecast BCTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCTX is 39.90 USD with a low forecast of 39.90 USD and a high forecast of 39.90 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.640
Low
39.90
Averages
39.90
High
39.90
Current: 7.640
Low
39.90
Averages
39.90
High
39.90
About BCTX
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
